Clinical Trial · NCT06852807

18F-mFBG PET Imaging in the Evaluation of Neuroblastoma

Overview

The aim of this study is to evaluate the diagnostic performance and tumor burden of 18F-metafluorobenzylguanidine (18F-MFBG) positron emission tomography (PET) in patients with neuroblastoma.

Sponsor

First Affiliated Hospital of Zhejiang University

Contacts

Peipei Wang, MD (CONTACT)

wpp199411@163.com

86 18511395988

ClinicalTrials.gov

NCT06852807

Drug / Compound

MFBG

Isotope(s):

Target(s):

Ligand Class: Small Molecules

Eligibility

Inclusion

Clinically suspected or confirmed patients with neuroblastoma;

Exclusion

Patients who have received ionizing radiation outside the scope of this experiment for other clinical medical or scientific research purposes within the past year, resulting in an annual radiation exposure dose exceeding 50 mSv.
Patients with severe primary diseases such as heart, brain, liver, kidney and hematopoietic system diseases;
Patients with any condition that the principal investigator of this study deems may cause harm or potential harm in any aspect related to this trial.
Patients who have received experimental drugs or devices (with uncertain efficacy or safety) within one month;